Corixa [CRXA] - cancer vaccines Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (172)	2/24/2003 8:35:45 PM
From: SemiBull	Read Replies (1) of 222

Corixa: Europe Commission Designates Bexxar Orphan Pdt Monday February 24, 5:01 pm ET SEATTLE (Dow Jones)--Corixa Corp. said its follicular lymphoma therapy called Bexxar was granted orphan status by the European Agency for the Evaluation of Medicinal Products. In a press release Monday, Corixa said if approved, the product will be entitled to 10-year market exclusivity in Europe. Corixa shares were trading up 5% after hours at $5.66, after closing the regular session down 4% at $5.40.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next